Document is current

Any future updates will be listed below

626 Trial in progress: an intravenously administered second-generation STING agonist, BI 1703880 with a novel lead-in design in combination with ezabenlimab

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.0626

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark